ARGX
Price
$843.66
Change
+$6.38 (+0.76%)
Updated
Oct 17 closing price
Capitalization
50.99B
11 days until earnings call
HALO
Price
$67.03
Change
+$0.15 (+0.22%)
Updated
Oct 17 closing price
Capitalization
7.84B
22 days until earnings call
Interact to see
Advertisement

ARGX vs HALO

Header iconARGX vs HALO Comparison
Open Charts ARGX vs HALOBanner chart's image
argenx SE
Price$843.66
Change+$6.38 (+0.76%)
Volume$452.51K
Capitalization50.99B
Halozyme Therapeutics
Price$67.03
Change+$0.15 (+0.22%)
Volume$2.24M
Capitalization7.84B
ARGX vs HALO Comparison Chart in %
ARGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARGX vs. HALO commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGX is a Hold and HALO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (ARGX: $843.66 vs. HALO: $67.03)
Brand notoriety: ARGX and HALO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGX: 128% vs. HALO: 105%
Market capitalization -- ARGX: $50.99B vs. HALO: $7.84B
ARGX [@Biotechnology] is valued at $50.99B. HALO’s [@Biotechnology] market capitalization is $7.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGX’s FA Score shows that 1 FA rating(s) are green whileHALO’s FA Score has 2 green FA rating(s).

  • ARGX’s FA Score: 1 green, 4 red.
  • HALO’s FA Score: 2 green, 3 red.
According to our system of comparison, ARGX is a better buy in the long-term than HALO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARGX’s TA Score shows that 4 TA indicator(s) are bullish while HALO’s TA Score has 5 bullish TA indicator(s).

  • ARGX’s TA Score: 4 bullish, 4 bearish.
  • HALO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, HALO is a better buy in the short-term than ARGX.

Price Growth

ARGX (@Biotechnology) experienced а +5.87% price change this week, while HALO (@Biotechnology) price change was +4.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

ARGX is expected to report earnings on Oct 30, 2025.

HALO is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARGX($51B) has a higher market cap than HALO($7.84B). ARGX has higher P/E ratio than HALO: ARGX (42.93) vs HALO (15.34). HALO YTD gains are higher at: 40.201 vs. ARGX (37.180). HALO has higher annual earnings (EBITDA): 792M vs. ARGX (690M). ARGX has more cash in the bank: 3.93B vs. HALO (548M). ARGX has less debt than HALO: ARGX (43.2M) vs HALO (1.51B). ARGX has higher revenues than HALO: ARGX (3.05B) vs HALO (1.18B).
ARGXHALOARGX / HALO
Capitalization51B7.84B651%
EBITDA690M792M87%
Gain YTD37.18040.20192%
P/E Ratio42.9315.34280%
Revenue3.05B1.18B259%
Total Cash3.93B548M717%
Total Debt43.2M1.51B3%
FUNDAMENTALS RATINGS
ARGX vs HALO: Fundamental Ratings
ARGX
HALO
OUTLOOK RATING
1..100
2865
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
1133
SMR RATING
1..100
3911
PRICE GROWTH RATING
1..100
4051
P/E GROWTH RATING
1..100
6272
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HALO's Valuation (77) in the Biotechnology industry is in the same range as ARGX (81) in the Pharmaceuticals Other industry. This means that HALO’s stock grew similarly to ARGX’s over the last 12 months.

ARGX's Profit vs Risk Rating (11) in the Pharmaceuticals Other industry is in the same range as HALO (33) in the Biotechnology industry. This means that ARGX’s stock grew similarly to HALO’s over the last 12 months.

HALO's SMR Rating (11) in the Biotechnology industry is in the same range as ARGX (39) in the Pharmaceuticals Other industry. This means that HALO’s stock grew similarly to ARGX’s over the last 12 months.

ARGX's Price Growth Rating (40) in the Pharmaceuticals Other industry is in the same range as HALO (51) in the Biotechnology industry. This means that ARGX’s stock grew similarly to HALO’s over the last 12 months.

ARGX's P/E Growth Rating (62) in the Pharmaceuticals Other industry is in the same range as HALO (72) in the Biotechnology industry. This means that ARGX’s stock grew similarly to HALO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARGXHALO
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
65%
Bullish Trend 2 days ago
63%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
66%
MACD
ODDS (%)
Bullish Trend 2 days ago
63%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 24 days ago
62%
Bearish Trend 9 days ago
67%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
68%
Aroon
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
ARGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HCMT37.550.37
+0.98%
Direxion HCM Tactical EnhU.S.EqStratETF
VOOV198.901.27
+0.64%
Vanguard S&P 500 Value ETF
MVV67.140.27
+0.41%
ProShares Ultra MidCap400
BBIB100.10N/A
N/A
JPMorgan BetaBuilders U.S.TrsBd3-10YrETF
DVSP26.53-0.83
-3.02%
WEBs Defined Volatility SPY ETF

ARGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with ARGNF. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then ARGNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARGX
1D Price
Change %
ARGX100%
+0.76%
ARGNF - ARGX
55%
Loosely correlated
N/A
ALNY - ARGX
42%
Loosely correlated
+0.12%
AXON - ARGX
40%
Loosely correlated
+2.84%
GMAB - ARGX
37%
Loosely correlated
+1.28%
ROIV - ARGX
36%
Loosely correlated
+0.88%
More

HALO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HALO has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HALO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HALO
1D Price
Change %
HALO100%
+0.22%
AXON - HALO
47%
Loosely correlated
+2.84%
XENE - HALO
44%
Loosely correlated
-1.28%
IRON - HALO
37%
Loosely correlated
+20.95%
TECH - HALO
37%
Loosely correlated
+0.42%
ARGX - HALO
35%
Loosely correlated
+0.76%
More